Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

February 28, 2024Open Access

Ver artículo completo

Cost-effectiveness of nonavalent HPV vaccination in the Netherlands

CPCody PalmerMerck & Co., Inc., Rahway, NJ, USA (United States)FDF Christiaan K DolkMSD (Netherlands)USUgne SabaleMSD (Lithuania)

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Background A bivalent human papillomavirus vaccine (2vHPV) is currently used in the Netherlands; a nonavalent vaccine (9vHPV) is also licensed.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Palmer et al. (Wed,) studied this question.

synapsesocial.com/papers/68e77206b6db6435876e6db0 https://doi.org/https://doi.org/10.1080/14760584.2024.2322543

Cost-effectiveness of nonavalent HPV vaccination in the Netherlands | Synapse